Connect Biopharma

Immune Modulation


HBM contact: Dr Ivo Staijen, Dr Michael Buschle

Company status: public

Connect Biopharma is a clinical stage company focused on identifying and developing potent and specific immune modulation molecules. The two lead assets of the company are in clincal trials in atopic dermatitis and ulcerative colitis. Additional indications will be explored in the future.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171